{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:04:00Z","timestamp":1771232640029,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"am","delay-in-days":399,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.therap.2021.12.006","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T23:33:33Z","timestamp":1639265613000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase\u00ae"],"prefix":"10.1016","volume":"77","author":[{"given":"Mathilde","family":"Strumia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Loup","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Patras de Campaigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2021.12.006_bib0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1186\/s12885-018-4984-3","article-title":"The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study","volume":"18","author":"Di Felice","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.therap.2021.12.006_bib0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.2016.1145654","article-title":"Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"15","author":"Breccia","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2021.12.006_bib0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.therap.2021.12.006_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/17474086.2015.1041910","article-title":"Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events","volume":"8","author":"Carneiro","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.therap.2021.12.006_bib0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0160","series-title":"Cancer today","author":"International agency for Research on Cancer","year":"2021"},{"key":"10.1016\/j.therap.2021.12.006_bib0165","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2021.12.006_bib0170","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.therap.2021.12.006_bib0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.therap.2021.12.006_bib0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: Inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11864-013-0254-4","article-title":"Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management","volume":"14","author":"Belum","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.therap.2021.12.006_bib0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.therap.2021.12.006_bib0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1529-8019.2011.01432.x","article-title":"Dermatologic manifestations of cytotoxic therapy","volume":"24","author":"Huang","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2021.12.006_bib0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0205","first-page":"35","article-title":"Body image disturbance in patients with acne vulgaris","volume":"4","author":"Bowe","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0019-5154.92672","article-title":"Physical and psychosocial impact of acne in adult females","volume":"57","author":"Pruthi","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0215","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2021.12.006_bib0220","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.therap.2021.12.006_bib0225","doi-asserted-by":"crossref","first-page":"902e2","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0230","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0235","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","article-title":"Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy","volume":"79","author":"Rzepecki","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2021.12.006_bib0240","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.therap.2021.12.006_bib0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.therap.2021.12.006_bib0250","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/bcp.13238","article-title":"Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics","volume":"83","author":"Patras de Campaigno","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.12.006_bib0255","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/bcp.13693","article-title":"Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from VigiBase","volume":"84","author":"Mah\u00e9","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.12.006_bib0260","doi-asserted-by":"crossref","first-page":"1802472","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study","volume":"53","author":"Cornet","year":"2019","journal-title":"Eur Respir J"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:29:26Z","timestamp":1715030966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721002572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0040595721002572"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase\u00ae","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}